Mechanistically, inhibiting JAK2 disrupted downstream STAT signaling, which is constitutively activated in ATLL and crucial for maintaining anti-apoptotic BCL-2 family protein expression. The gene discussed is BCL2; the disease is adult T-cell leukemia/lymphoma.